Cresset Asset Management Invests $1.95M in Aardvark Therapeutics

The investment firm bought a new stake in the biotech company focused on RORγ modulators.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Cresset Asset Management LLC purchased 146,783 shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) in the third quarter, valued at approximately $1.95 million. Aardvark is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts that specializes in developing small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ), which plays a central role in inflammatory processes.

Why it matters

The investment from Cresset Asset Management represents a significant vote of confidence in Aardvark's RORγ-targeting pipeline, which aims to address a range of autoimmune and immune-mediated diseases. As the company advances its lead programs in conditions like psoriasis and inflammatory bowel disease, this funding will help support its research and development efforts.

The details

According to the 13F filing, Cresset Asset Management purchased 146,783 shares of Aardvark Therapeutics in the third quarter. Other notable investors that have added to or reduced their stakes in the company include Vanguard Group, Bank of America, and Geode Capital Management.

  • Cresset Asset Management made the investment in the third quarter of the year.
  • Aardvark Therapeutics' stock opened at $5.85 on Friday, March 8, 2026.

The players

Cresset Asset Management LLC

An investment management firm that purchased a new stake in Aardvark Therapeutics.

Aardvark Therapeutics, Inc.

A clinical-stage biopharmaceutical company based in Cambridge, Massachusetts that is developing small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ).

Got photos? Submit your photos here. ›

The takeaway

Cresset Asset Management's investment in Aardvark Therapeutics signals growing investor interest in the company's RORγ-targeting pipeline and its potential to address a range of autoimmune and inflammatory conditions. As Aardvark continues to advance its lead programs, this funding will help support its ongoing research and development efforts.